TP53 and neoplasm: CMA degrades proteins with oncogenic potential like CIP2A (Gomes et al., 2017), MDM2 (Lu et al., 2010), and mutant TP53 (Vakifahmetoglu-Norberg et al., 2013), providing tumor-suppressive functions.